The FDA announced that it is banning 28 prescription drugs from Ranbaxy Laboratories after discovering production lapses at two of the generic-drug firm's facilities in India. An agency official said there was "no evidence of harm to consumers" based on contamination tests. Ranbaxy expressed disappointment with the decision, saying it responded to all concerns that the FDA raised during the past two years.

Related Summaries